Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RICHARD SANDERS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1730142365
CMS profile
810988
Location
DAYTON, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$71.88

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $71.88 3

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Lundbeck LLC $51.90 2
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $19.98 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RICHARD SANDERS

NPI 1730142365 · CMS profile ID 810988

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

DAYTON, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1730142365?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RICHARD SANDERS, NPI 1730142365, CMS profile ID 810988. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730142365?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). RICHARD SANDERS, NPI 1730142365, CMS profile ID 810988. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730142365?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
RICHARD SANDERS, NPI 1730142365, CMS profile ID 810988, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1730142365?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $71.88 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lundbeck LLC $22.1512/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251844047 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $19.9811/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241394671 CMS
Lundbeck LLC $29.7509/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251844045 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2025 $71.88 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $725,804.81 104
PY2024 Principal investigator $563,851.77 79
PY2023 Recipient $760.01 11
PY2023 Principal investigator $543,366.08 41
PY2022 Principal investigator $672.88 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

79 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,200.00 12/26/2024 Non-covered Recipient Entity
Evolution Research Group
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia No dispute reported 06/30/2026 1123477216
Principal investigator 1 Indivior Inc. $1,003.05 12/10/2024 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1144119338
Principal investigator 1 Indivior Inc. $15,800.00 11/21/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144119222
Principal investigator 1 Indivior Inc. $15,353.69 10/29/2024 Non-covered Recipient Entity
ERG - MIDWEST CLINICAL RESEARCH CENTER LLC
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1144118796
Principal investigator 1 Indivior Inc. $570.46 10/18/2024 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1144118436
Principal investigator 1 Indivior Inc. $94.50 10/09/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144118364
Principal investigator 1 Indivior Inc. $1,200.00 10/09/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144118366
Principal investigator 1 Indivior Inc. $1,030.00 10/09/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144118382
Principal investigator 1 Indivior Inc. $189.00 10/04/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144118306
Principal investigator 1 Indivior Inc. $141.00 10/04/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144118308
Principal investigator 1 Indivior Inc. $101.25 10/04/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144118312
Principal investigator 1 Indivior Inc. $577.06 09/30/2024 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1144118276
Principal investigator 1 Indivior Inc. $5,000.00 09/23/2024 Non-covered Recipient Entity
ERG - MIDWEST CLINICAL RESEARCH CENTER LLC
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1144118232
Principal investigator 1 Indivior Inc. $2,640.00 09/18/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144118212
Principal investigator 1 Indivior Inc. $13,750.00 09/16/2024 Non-covered Recipient Entity
ERG - MIDWEST CLINICAL RESEARCH CENTER LLC
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1144118024
Principal investigator 1 Indivior Inc. $4,176.45 09/12/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144118010
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,811.70 09/12/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144240672
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $34,020.00 09/12/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144240676
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $187.65 09/12/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144240682
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,185.20 09/12/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144240696
Principal investigator 1 Janssen Research & Development, LLC $140.00 09/09/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 1079004748
Principal investigator 1 Janssen Research & Development, LLC $55.00 09/09/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 1079004810
Principal investigator 1 Janssen Research & Development, LLC $18,220.00 09/09/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 1079004818
Principal investigator 1 Indivior Inc. $1,512.00 09/05/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144117918
Principal investigator 1 Indivior Inc. $2,147.85 09/05/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144117920
Principal investigator 1 Indivior Inc. $67.50 09/05/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144117922
Principal investigator 1 Indivior Inc. $1,417.50 09/05/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144117924
Principal investigator 1 Indivior Inc. $297.00 09/05/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144117926
Principal investigator 1 Indivior Inc. $708.75 09/05/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144117928
Principal investigator 1 Indivior Inc. $264.60 09/05/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144117930
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $19,440.00 09/03/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144240674
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $186.30 09/03/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144240680
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,117.20 09/03/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144240694
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $127,980.00 08/22/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144240678
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $279.45 08/22/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144240688
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,526.60 08/22/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144240698
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $113.40 08/22/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144240700
Principal investigator 1 Indivior Inc. $2,724.90 07/30/2024 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1144117414
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $134.67 07/25/2024 Non-covered Recipient Entity
Evolution Research Group
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia No dispute reported 06/30/2026 1123477210
Principal investigator 1 Indivior Inc. $450.00 07/10/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144117122
Principal investigator 1 Janssen Research & Development, LLC $4,070.00 06/27/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 1079004824
Principal investigator 1 Boehringer Ingelheim International GmbH $68,519.00 05/24/2024 Non-covered Recipient Entity
Midwest Clinical Research Center
Phase II DRF study of NR2B modulation in MDD No dispute reported 06/30/2026 1101071209
Principal investigator 1 Vanda Pharmaceuticals Inc. $6,902.46 05/09/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
EVALUATION OF EFFICACY AND SAFETY OF ILOPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER No dispute reported 06/30/2026 1133923943
Principal investigator 1 Indivior Inc. $74.00 05/02/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116493
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $30.24 05/01/2024 Non-covered Recipient Entity
MDWST CLINICAL RSRCH CTR
Connex-X No dispute reported 06/30/2026 1101073123
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $58.03 05/01/2024 Non-covered Recipient Entity
MDWST CLINICAL RSRCH CTR
Connex-X No dispute reported 06/30/2026 1155144962
Principal investigator 1 Indivior Inc. $824.76 04/30/2024 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116459
Principal investigator 1 Indivior Inc. $828.00 04/12/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116249
Principal investigator 1 Indivior Inc. $222.00 04/04/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116205
Principal investigator 1 Indivior Inc. $148.00 04/04/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144116207
Principal investigator 1 Boehringer Ingelheim International GmbH $6,639.30 04/01/2024 Non-covered Recipient Entity
Midwest Clinical Research Center
Phase II DRF study of NR2B modulation in MDD No dispute reported 06/30/2026 1101071207
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $34,020.00 03/26/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144240660
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,734.40 03/26/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144240668
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $93.15 03/26/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144240670
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 03/18/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression No dispute reported 06/30/2026 1079004792
Principal investigator 1 Indivior Inc. $2,007.00 03/12/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115973
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $460.42 03/06/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144240650
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $460.42 03/04/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144240648
Principal investigator 1 Indivior Inc. $1,538.00 02/29/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115903
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $3,106.60 02/22/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF FIXED-DOSE BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN THE TREATMENT OF ADULTS WITH POST?TRAUMATIC STRESS DISORDER No dispute reported 06/30/2026 1118845434
Principal investigator 1 Indivior Inc. $222.00 02/15/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115767
Principal investigator 1 Indivior Inc. $2,204.00 02/15/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115769
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,405.04 02/15/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144240652
Principal investigator 1 Indivior Inc. $1,179.00 02/13/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115741
Principal investigator 1 Indivior Inc. $2,484.00 02/07/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115697
Principal investigator 1 Indivior Inc. $4,085.00 02/07/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115719
Principal investigator 1 Indivior Inc. $41.00 02/07/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115721
Principal investigator 1 Indivior Inc. $1,052.00 01/31/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115649
Principal investigator 1 Indivior Inc. $444.00 01/31/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115673
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $460.42 01/31/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144240658
Principal investigator 1 Indivior Inc. $245.48 01/30/2024 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115633
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,518.26 01/29/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144240656
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $11,239.21 01/17/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144240654
Principal investigator 1 Indivior Inc. $2,358.00 01/16/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115529
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $53,092.34 01/13/2024 Non-covered Recipient Entity
ERG Holding Company LLC Woodland Internation Research Group LLC
Connex-X No dispute reported 06/30/2026 1101073125
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $56,081.78 01/13/2024 Non-covered Recipient Entity
ERG Holding Company LLC Woodland Internation Research Group LLC
Connex-3 No dispute reported 06/30/2026 1101074579
Principal investigator 1 Indivior Inc. $1,538.00 01/09/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115477
Principal investigator 1 Indivior Inc. $444.00 01/05/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS INJECTION (RBP-6000) IN TREATMENT-SEEKING ADULT PARTICIPANTS WITH OPIOID USE DISORDER AND HIGH-RISK OPIOID USE No dispute reported 06/30/2026 1144115467
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $1,208.73 01/01/2024 Non-covered Recipient Entity
MDWST CLINICAL RSRCH CTR
Connex-3 No dispute reported 06/30/2026 1101069731